心臓再同期療法市場（金額、数量、ASP）：セグメント別規模、シェア、動向およびSWOT分析、法規制および償還動向、手技、2033年までの予測

心臓再同期療法は、非同期化した心臓により良い生理的収縮パターンを回復させる選択肢として広く受け入れられています。二次情報によれば、CRTは患者の罹患率と死亡率を大規模に減少させることが証明されています。

心室同期障害、心室間伝導遅延、心室頻拍、心室細動は、患者の症状や生存率の大幅な改善につながるため、心臓再同期療法の基礎となっています。

当レポートは、世界の心臓再同期療法市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。

目次

現在上市されている心臓再同期療法と競合情勢

• 主要な業界動向の洞察
• 心臓再同期療法のセグメント別総市場収益と2015年～2033年の市場展望
• セグメント別の手技総数、台数、平均販売価格、市場価値に関する詳細データ

世界、地域、国別の洞察

• 心臓再同期療法市場のSWOT分析
• 心臓再同期療法市場に関する競合力学の洞察と動向
• 国別の医療制度の概要
• 国別の償還政策
• 国別の医療技術に関する規制の状況

Abstract

Cardiac Resynchronisation Therapy Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast to 2033 is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.

The model discusses in detail the impact of COVID-19 on Cardiac Resynchronisation Therapy market for the year 2020 and beyond. Cardiac Resynchronisation Therapy has become a widely accepted option which restores a better physiological pattern of contractions to the desynchronized hearts. Secondary sources indicate that CRT has proven to reduce the morbidity and mortality in patients at a large scale.

Ventricular Dyssynchrony, Interventricular Conduction Delay, Ventricular Tachycardia and Ventricular Fibrillation have become the basis of Cardiac Resynchronisation Therapy as it leads to significant improvements in symptoms and survival of patients.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Cardiac Resynchronisation Therapy and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total Cardiac Resynchronisation Therapy market revenue by segment and market outlooks from 2015-2033.
• Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Cardiac Resynchronisation Therapy market.
• Competitive dynamics insights and trends provided for Cardiac Resynchronisation Therapy market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Medtronic Plc, Abbott Laboratories, Biotronik SE & Co KG, Boston Scientific Corp, MicroPort Scientific Corp, EBR Systems Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Cardiac Resynchronisation Therapy marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Cardiac Resynchronisation Therapy market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Cardiac Resynchronisation Therapy market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Cardiac Resynchronisation Therapy market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Cardiac Resynchronisation Therapy market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.